China’s BCMA CAR-T Therapy Offers Last Hope for Relapsed Multiple Myeloma Patients

### China’s BCMA CAR-T Therapy Offers Last Hope for Relapsed Multiple Myeloma Patients

CAR-T Therapy

Multiple myeloma remains a difficult-to-cure disease, and every year, countless patients around the world face this devastating diagnosis. While treatment options have improved in recent years, and patients’ survival times have extended, drug resistance remains a significant challenge. For patients who have experienced multiple relapses and are resistant to various treatments, the future can seem bleak. Fortunately, with the emergence of **BCMA CAR-T cell therapy**, a new ray of hope is illuminating the path for these patients.

This is the story we’re sharing today, about a 76-year-old female patient who regained control of her life through CAR-T therapy.

#### The First Encounter with the Disease

In 2020, this Chinese 76-year-old woman noticed a decline in appetite and a rapid weight loss, accompanied by persistent rib pain. She had no idea that these symptoms were early signs of multiple myeloma. After several medical tests, her Chinese doctors confirmed the diagnosis: 31% of her bone marrow cells were plasma cells, her M-protein levels reached 85.7 g/L, and calcium levels in her blood were abnormally high. Multiple bones throughout her body also showed signs of significant damage.

The diagnosis left the patient shocked and confused. Multiple myeloma wasn’t her first health challenge; she also had a history of Parkinson’s disease. However, she remained hopeful, believing that with the right treatment, her condition could be controlled. But fate had other plans.

#### The Struggle and Relapse

At the beginning of 2023, the patient’s condition relapsed rapidly. Due to a prolonged lack of regular treatment, her disease worsened, and she became resistant to many standard therapies. After extensive tests, her medical team discovered that she had a high-risk mSMART 3.0 profile, with genetic abnormalities including 1q21 amplification and a t(4;14) translocation, making her prognosis extremely poor. She was now considered a “triple-refractory” patient, resistant to three main treatment categories.

Faced with this complex and challenging situation, the Chinese doctors didn’t give up. After multiple discussions and research, they recommended a cutting-edge therapy — **BCMA CAR-T cell therapy**. This treatment involves modifying the patient’s immune cells to target and destroy cancer cells. However, to undergo this advanced therapy, the patient first needed to undergo **bridging treatment** to reduce the tumor burden in her body.

#### Bridging Treatment: A Turning Point

To prepare for CAR-T therapy, the Chinese doctors initially prescribed the **DKD regimen**, a combination therapy intended to quickly reduce the cancer cell load. However, the first treatment cycle didn’t bring significant improvement, and her free light chain levels remained high. Both the patient and her family felt disappointed, but the Chinese doctors acted quickly, switching to the **KAD regimen**, which included **liposomal doxorubicin** to further enhance the treatment’s effectiveness.

This adjustment brought immediate results. After a few weeks, her free light chain levels began to drop, and her condition showed partial remission (PR). This meant she was finally ready for CAR-T cell therapy.

#### The Miracle of CAR-T Therapy

CAR-T therapy is a breakthrough technology where the patient’s immune cells are extracted, genetically modified to recognize and destroy cancer cells, and then reintroduced into the body. These engineered cells act like precision-guided weapons, specifically targeting her cancer cells.

The patient responded positively to the treatment. Within just a few weeks, her condition was significantly controlled, with results showing a very good partial response (VGPR). For such a complex case of relapsed and refractory disease, this was a major success.

#### The Significance of the Story

This patient’s story highlights China’s latest advancements in the treatment of multiple myeloma. The use of **carfilzomib-based bridging therapy** paved the way for CAR-T therapy, successfully giving a patient with a poor prognosis a new chance at life. For those facing the dual challenges of drug resistance and relapse, **BCMA CAR-T therapy** offers not just a new treatment option, but a lifeline.

The product that has renewed hope for this 76-year-old Chinese woman is a BCMA-targeted CAR-T therapy that has already been launched in China. China is changing the fate of patients worldwide through advanced cancer treatments. Notably, in the field of CAR-T technology related to hematologic tumors and multiple myeloma, two BCMA CAR-T products have been approved in China. Especially commendable is Reindeer Bio’s independently developed fully human BCMA product, FUCASO, which has achieved an astonishing complete remission (CR) rate of 82.4%, the highest among all globally approved products. An increasing number of foreign multiple myeloma patients are now seeking treatment in China to access better therapies at more affordable prices. As China continues to develop cutting-edge medical therapies, aggressive treatments like CAR-T undoubtedly provide new hope for the future of multiple myeloma treatment.

Follow us for more stories of medical innovation and to witness how miracles of life are born in China!

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#MultipleMyeloma #CancerTreatment #CAR_TTherapy #BCMACAR_T #CancerSurvivor #Immunotherapy #ChinaMedicalInnovation #CancerResearch #CancerHope #MedicalBreakthrough #MyelomaAwareness #AdvancedCancerCare #RelapsedMyeloma #LifeSavingTreatment #PatientSuccessStory #CancerCare #GlobalHealth #CAR_TSuccess #Oncology #CancerSupport

#ChineseMedical #ChinaHealthcare #MedicalCareInChina #HealthcareInChina ·  #USMedical #USHealthcare  #HealthcareInUSA #AmericanMedical #MedicalCareInUSA #USAHealth #AmericanHealthcare

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

3 months ago Solid tumor

Hope to Eradicate Lung Cancer, Colorectal Cancer, and Various Solid Tumors! China’s First Self-Replicating mRNA Vaccine JCXH-211 Successfully Launched~

Hope to Eradicate Lung Cancer, Colorectal Cancer, and Various Solid Tumors! China’s First Self-Replicating mRNA Vaccine JCXH-211 Successfully Launched~

mRNA Vaccine

Tumor immunotherapy, as an emerging method for diagnosing and treating tumors, has garnered widespread attention since its inception. Prior to the advent of tumor immunotherapy, the clinical treatment of solid tumors relied solely on traditional surgical removal, radiotherapy, and chemotherapy. Although these methods were effective, they came with significant drawbacks such as drug side effects and the risk of recurrence.

Since the 1990s, mRNA vaccines have been considered therapeutic vaccines. During the COVID-19 pandemic in 2020, mRNA vaccines were used in clinical treatments, saving countless lives. Today, as the advantages of mRNA vaccines are gradually being discovered, they are now applied in multiple fields.

The advent of China’s first self-replicating mRNA vaccine JCXH-211 undoubtedly marks a new breakthrough in the clinical diagnosis and treatment of various solid tumors in China.

**What is the mRNA Vaccine JCXH-211?**

JCXH-211 is the world’s first self-replicating RNA drug encoding human interleukin-12 (IL-12) to enter clinical trials. This srRNA vaccine delivers mRNA encoding IL-12 into the cytoplasm, continuously expressing IL-12 to enhance the body’s immune response against tumor cells.

In preclinical studies involving various mouse and PDX disease models, JCXH-211 has shown the ability to effectively kill tumor cells, eliminate distant tumors, and prevent tumor recurrence. Comprehensive GLP toxicology studies have also demonstrated good safety.

JCXH-211 has a broad range of indications and is expected to effectively treat multiple solid tumors. The anticipated prospects are as follows:

**1. Lung Cancer:**

As one of the leading causes of cancer death worldwide, lung cancer is often diagnosed at a late stage due to difficulties in early detection. JCXH-211, through continuous expression of IL-12 and activation of immune cells, is expected to effectively control the growth and spread of lung cancer cells.

**2. Colorectal Cancer:**

Current clinical treatments for colorectal cancer primarily involve surgery and radiotherapy/chemotherapy, which can remove visible tumors but have a high recurrence rate. Periodic administration of JCXH-211 may significantly reduce recurrence and improve patient survival.

**3. Soft Tissue/Chondrosarcoma:**

These tumors are highly invasive and cover a wide range of areas, often affecting surrounding soft tissues and progressing rapidly. Current treatments are limited to surgery and radiotherapy/chemotherapy, which, although somewhat effective, are not thorough, leading to high recurrence rates. JCXH-211 could become a new treatment method, enhancing the body’s immune response to combat these stubborn cancer cells.

**4. Skin Cancer:**

Clinical treatments for skin cancer mainly include surgery and radiotherapy. While most skin cancers have a good prognosis, the effects on intractable melanoma are poor. The expression of IL-12 can activate specific T cells, greatly aiding in the elimination of melanoma cells.

**High-Efficiency Activation and Safety of the mRNA Vaccine JCXH-211!**

mRNA vaccines not only encode antigens to induce specific immune responses against tumors but also possess inherent immunostimulatory properties. This dual mechanism allows JCXH-211 to activate the immune system more efficiently, enhancing the overall anti-tumor effect.

Moreover, the safety of mRNA vaccines is well-recognized. Since DNA is the genetic material of most species, including humans and viruses, and is transcribed into mRNA before being translated into proteins to perform functions in the body, injecting mRNA into the human body does not enter the cell nucleus, thereby eliminating the risk of genomic insertion mutations. Additionally, mRNA can be naturally degraded and excreted from the body, preventing accumulation. Thus, JCXH-211 presents lower potential risks and is safer.

Currently, clinical trials are progressing steadily. With the rapid advancement of tumor immunotherapy, JCXH-211 is expected to become a standard treatment for various solid tumors, offering hope to many cancer patients.

To assess whether the condition is suitable for cancer vaccine or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#LungCancer #ColorectalCancer #SolidTumors #mRNAVaccine #JCXH211 #CancerTreatment #TumorImmunotherapy #MedicalBreakthrough #Biopharma #CancerResearch #HealthcareInnovation #CancerHope #MedicalScience #HealthTech #ClinicalTrials #CancerSurvivor #CancerAwareness #InnovativeMedicine #CancerVaccine #Vaccine #mRNA #JCXH